Ratings by Jefferies (Akash Tewar)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/2/2026 | Zymeworks | ZYME | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2025 | Zymeworks | ZYME | Maintain | Buy (N/A) |
|
Details | ||
| 11/17/2025 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 1/17/2025 | Sage Therapeutics | SAGE | Maintain | Hold (N/A) |
|
Details | ||
| 11/21/2024 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 11/29/2023 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 9/1/2023 | Horizon Therapeutics | HZNP | Downgrade | Hold (Buy) |
112.74 (116.30) |
3.16% | Details | |
| 5/17/2023 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 12/20/2022 | Zymeworks | ZYME | Upgrade | Buy (Hold) |
6.46 (24.08) |
272.76% | Details | |
| 12/1/2022 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 3/16/2022 | Jazz Pharmaceuticals | JAZZ | Maintain | Buy (N/A) |
|
Details | ||
| 10/7/2021 | Jazz Pharmaceuticals | JAZZ | New Coverage | Buy (N/A) |
128.08 (182.01) |
42.11% | Details | |
| 10/7/2021 | BioMarin Pharmaceutical Inc. | BMRN | New Coverage | Buy (N/A) |
76.73 (61.12) |
-20.34% | Details | |
| 10/7/2021 | Exelixis | EXEL | New Coverage | Buy (N/A) |
20.91 (41.55) |
98.71% | Details | |
| 10/7/2021 | Zymeworks | ZYME | New Coverage | Hold (N/A) |
28.08 (24.08) |
-14.25% | Details | |
| 10/7/2021 | Sage Therapeutics | SAGE | New Coverage | Hold (N/A) |
45.02 (8.68) |
-80.72% | Details | |
| 10/7/2021 | Horizon Therapeutics | HZNP | New Coverage | Buy (N/A) |
113.84 (116.30) |
2.16% | Details |
